Novartis data show multiple sclerosis patients and nurses prefer Kesimpta (ofatumumab) Sensoready autoinjector pen

  • Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84% vs 16%)1
  • Sensoready autoinjector pen ranked highest for "easy to perform self-injection with the pen," "patient able to use independently" and "ease of preparation and set-up" by both patients and nurses1
  • Kesimpta is a targeted B-cell therapy that delivers superior efficacy and post hoc analysis showed that nearly nine out of 10 patients treated with Kesimpta achieved no evidence of disease activity (NEDA-3) in their second year of treatment2
  • Kesimpta received positive CHMP opinion last month based on two phase III trials where Kesimpta showed a reduction of annual relapses by over 50% with more than 30% relative risk reduction of 3 months confirmed disability progression (CDP) compared with teriflunomide, a first-line treatment in MS3



Basel, February 16, 2021 - Novartis announced today new multicenter survey results showing that people living with multiple sclerosis (MS) and nurses prefer the Sensoready autoinjector pen for self-administration of Kesimpta (ofatumumab) over other autoinjectors used for other disease-modifying therapies in MS1. These data, which will be presented at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS) taking place on February 25-27, 2021, continue to show that Kesimpta has the potential to become a first-choice treatment option, as ease of administration plays an important role in patient satisfaction and treatment adherence.

"As an MS nurse, it’s important for me to know that the people I work with who have MS are going to be successful in administering their treatment themselves," said Amy Perrin Ross. "The Sensoready autoinjector pen is easy to set up and use, so people living with MS can feel confident that they will be able to administer the treatment themselves independently and comfortably."

"For people living with a chronic disease such as MS, access to highly effective treatments and maintaining flexibility in their lives is paramount," said Estelle Vester-Blokland, Global Head Neuroscience Medical Affairs, Novartis Pharmaceuticals. "At Novartis, we are committed to reimagining medicine and solutions that enable patients to maintain that flexibility in their daily lives by having a safe, high efficacy treatment that is easy to use independently from the comfort of their own home."

About the study1
The multicenter survey was conducted with 80 MS patients and 50 MS nurses across the US, Germany, France and Italy. The survey included patients with RMS who received a disease-modifying treatment through a subcutaneous/intramuscular injection via an autoinjector for